Editorial |

Important Data After Drug Approval:  Comment on “Dabigatran Association With Higher Risk of Acute Coronary Events”

Rita F. Redberg, MD
Arch Intern Med. 2012;172(5):404. doi:10.1001/archinternmed.2011.2169.
Text Size: A A A
Published online


Continued data collection and analysis allow us to learn important additional information about new drugs after US Food and Drug Administration approval. In the case of dabigatran, we have recently learned that the lack of ability to monitor the bleeding level and serious bleeding episodes associated with deaths have led to safety warnings in Australia and Japan and a renal assessment advisory by the European Medicines Agency. The lack of a reversal agent has been associated with deaths among trauma victims who are receiving dabigatran. A recent Medco Health Solutions report found that the actual stroke and bleeding rates found at 4 months for dabigatran were equivalent to or higher than the stroke and bleeding rates per year for warfarin from the RE-LY trial. Now, Uchino and Hernandez highlight an additional serious concern for dabigatran—an increased relative risk of 27% to 33% of MI and ACS. These additional concerns deserve serious consideration in weighing the risks and benefits of dabigatran and highlight the importance of continued collection and analysis of data after drug approval.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Related Topics